Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Colon Cancer
17-Allylamino-17-demethoxygeldanamycin overcame TRAIL resistance in colon cancer
September 14th, 2005
17-allylamino-17-demethoxygeldanamycin (17-AAG) overcame tumor necrosis factor related apoptosis-inducing ligand (TRAIL) resistance in colon cancer. According to a study from the United States, "TRAIL is a promising candidate for treatment of cancer but displays variable cytotoxicity in cell lines. The mechanisms of sensitivity and resistance have not been fully elucidated; both AKT and NF-kappaB pathways may modulate cytotoxic responses." "We have shown that the Hsp90 inhibitor 17-AAG enhances the cytotoxicity of oxaliplatin in colon cancer cell lines through inhibition of NF-kappaB. We analyzed the effects of TRAIL and 17-AAG in combination in a...
Source: Vaccine Weekly (2005-09-14)
|
